Researchers found a 30% increased risk of cardiovascular events in patients whose diagnosis was delayed by more than a year after an elevated blood pressure reading.
Diagnostic delays for hypertension are associated with significantly lower treatment rates and increased long-term cardiovascular risk, according to a cohort study of more than 300,000 adults with hypertension.1
Researchers used electronic health record (EHR) data to identify patients with at least 2 blood pressure (BP) readings of 140/90 mm Hg or higher recorded at least 30 days apart between 2010 and 2021. These patients met the criteria for a “computed hypertension diagnosis” but experienced varying times to formal clinical diagnosis by a provider. The findings were published in JAMA Network Open.
Patients with delayed hypertension diagnoses were not disengaged from care. | Image credit: CasanoWa Stutio – stock.adobe.com
Among the 311,743 patients included, 14.6% received a clinical hypertension diagnosis more than 30 days after their second elevated BP reading. Compared with those whose hypertension was diagnosed between their first and second BP reading, patients with delayed diagnoses were far less likely to receive antihypertensive medications within 30 days (30.6% vs 75.2%; P < .001).
Prescription rates decreased progressively with longer diagnostic delays. Just 26.4% of those diagnosed more than 365 days after the second BP reading received treatment, compared with 54.5% for delays up to 90 days.
These delays had consequences, according to the authors. Over a 5-year follow-up period, the risk of major cardiovascular events—including heart failure hospitalization, ischemic stroke, or heart attack—rose in tandem with diagnostic delay. Compared with timely diagnoses, delayed diagnoses were tied to a:
Subgroup analyses in the current study confirmed that the association between delayed diagnosis and worse outcomes held across age, sex, and racial/ethnic groups.
The nearly 30% higher risk of cardiovascular events for patients receiving a diagnosis more than a year late is consistent with previous findings, according to the authors. For example, a BMJ study of more than 88,000 patients in the UK found that delaying medication intensification for more than 1.4 months after a systolic BP elevation was linked to a 12% higher risk of cardiovascular events or death; waiting more than 2.7 months for a follow-up visit after starting or adjusting antihypertensive treatment also raised the risk by 18%.2 Cardiovascular risk significantly increased when BP was not addressed until levels exceeded 150 mm Hg.
Importantly, patients with delayed diagnoses were not disengaged from care.1 They had a similar number of outpatient visits prior to the second elevated BP reading and often had substantial continued interaction with the health system afterward, according to the study. In fact, longer delays were associated with more follow-up visits, suggesting missed opportunities rather than a lack of access.
At the same time, there are other factors to consider, as some diagnostic delays could stem from appropriate clinical caution. For example, clinicians might hesitate to diagnose hypertension after a single high reading due to concerns about white-coat hypertension or temporary spikes caused by something as simple as a cup of coffee. Additionally, current guidelines—last updated in 2017—advise confirming sustained high BP and prioritizing lifestyle changes for patients at low risk before starting medication.3
“However, the consistently lower rates of antihypertensive medication prescriptions among patients with delayed diagnoses suggest that clinical caution alone does not fully account for the observed delays,” the authors added.1
They also observed longer diagnostic delays for younger adults, women, Black patients, and Asian patients, which may reflect underlying disparities in care due to implicit bias or differences in patient-clinician communication styles or symptom presentation.
The authors said these findings underscore the need for changes in hypertension detection, advocating for EHR-based clinical decision support tools to identify patients with elevated BP who meet diagnostic criteria, allowing clinicians to act in real time. Incorporating nonphysician health professionals into care teams could also improve hypertension detection and management. Meanwhile, pharmacists can lead BP screenings, adjust medications, and educate patients, especially in outpatient or community settings; nurses can assist with BP rechecks, education, and referrals for diagnostic confirmation.
“Embedding team-based care models within primary care practices may help distribute the workload and ensure that patients meeting hypertension criteria receive timely evaluation and diagnosis,” the authors said.
References
Dupilumab Shows Strong Efficacy in SCORAD-Based AD Assessment
July 14th 2025With few real-life studies that have specifically focused on how atopic dermatitis (AD) affects patients living with the chronic inflammatory skin condition in Latin American countries, the present authors investigated dupilumab-related outcomes among 100 patients using SCORing Atopic Dermatitis (SCORAD) index values.
Read More
Blister Packs May Help Solve Medication Adherence Challenges and Lower Health Care Costs
June 10th 2025Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.
Listen